{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:03:41Z","timestamp":1792040621606,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clml.2023.08.014","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:40:12Z","timestamp":1692618012000},"page":"866-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Updates in the Management of Primary Mediastinal B Cell Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Charbel","family":"Soueidy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.clml.2023.08.014_bib0001","doi-asserted-by":"crossref","first-page":"e4054","DOI":"10.1097\/MD.0000000000004054","article-title":"Racial patterns of patients with primary mediastinal large B-cell lymphoma","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.clml.2023.08.014_bib0002","doi-asserted-by":"crossref","first-page":"E436","DOI":"10.1002\/ajh.24485","article-title":"The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome","volume":"91","author":"Bledsoe","year":"2016","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2023.08.014_bib0003","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.08.014_bib0004","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"sup3","key":"10.1016\/j.clml.2023.08.014_bib0005","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1080\/10428190310001623810","article-title":"Pathobiology of primary mediastinal B-cell lymphoma","volume":"44","author":"Pileri","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0006","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2010.030809","article-title":"Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children","volume":"96","author":"Oschlies","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2023.08.014_bib0007","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/modpathol.2012.129","article-title":"Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers","volume":"25","author":"Dorfman","year":"2012","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/PAS.0000000000000771","article-title":"Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma","volume":"41","author":"Gentry","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0009","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.pas.0000213334.40358.0e","article-title":"Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma","volume":"31","author":"Rodig","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13000-019-0918-x","article-title":"Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma","volume":"14","author":"Kim","year":"2019","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clml.2023.08.014_bib0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"issue":"13","key":"10.1016\/j.clml.2023.08.014_bib0012","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2023.08.014_bib0013","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2023.08.014_bib0014","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.bjc.6601460","article-title":"Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B\/VACOP-B","volume":"90","author":"Todeschini","year":"2004","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.08.014_bib0016","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ijrobp.2006.12.048","article-title":"Primary Mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B\/VACOP-B) plus involved field radiotherapy on 53 patients. a single institution experience","volume":"68","author":"Mazzarotto","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clml.2023.08.014_bib0017","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-017-3332-3","article-title":"Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma","volume":"17","author":"Lisenko","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clml.2023.08.014_bib0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.14287","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial","volume":"175","author":"Gleeson","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.08.014_bib0021","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.21873\/invivo.12831","article-title":"Real-life experience with rituximab-CHOP Every 21 or 14 days in primary mediastinal large B-cell lymphoma","volume":"36","author":"Karakatsanis","year":"2022","journal-title":"In Vivo"},{"issue":"19","key":"10.1016\/j.clml.2023.08.014_bib0022","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","article-title":"Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study","volume":"5","author":"Camus","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.08.014_bib0023","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fcvm.2017.00066","article-title":"Radiation-induced cardiovascular disease: a clinical perspective","volume":"4","author":"Yusuf","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.clml.2023.08.014_bib0024","doi-asserted-by":"crossref","first-page":"444","DOI":"10.7326\/0003-4819-152-7-201004060-00009","article-title":"Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer","volume":"152","author":"Henderson","year":"2010","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.clml.2023.08.014_bib0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/10428194.2013.810738","article-title":"Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease","volume":"55","author":"Soumerai","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.clml.2023.08.014_bib0026","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2023.08.014_bib0027","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.08.014_bib0028","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOPversusdose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis","volume":"180","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2023.08.014_bib0029","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","article-title":"Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up","volume":"10","author":"Zhou","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ejh.13337","article-title":"Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma","volume":"104","author":"Malenda","year":"2019","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.08.014_bib0031","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.hemonc.2021.05.002","article-title":"Primary mediastinal large B-cell lymphoma\u202f: impact of chemotherapy choice","volume":"15","author":"Elhagracy","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"24","key":"10.1016\/j.clml.2023.08.014_bib0032","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1002\/cam4.4387","article-title":"Dose-adjusted EPOCH-R is not superior to sequential R-CHOP\/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: results of a bi-center retrospective study","volume":"10","author":"Morgenstern","year":"2021","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.clml.2023.08.014_bib0033","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ajh.24172","article-title":"Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis","volume":"90","author":"Giri","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.08.014_bib0034","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jayao.2019.0018","article-title":"Role of radiation therapy in younger and older adults with primary mediastinal large B cell lymphoma in rituximab era: a U.S. population-based analysis","volume":"8","author":"Jiang","year":"2019","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.08.014_bib0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ajh.24325","article-title":"Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma","volume":"91","author":"Jackson","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.08.014_bib0036","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3892\/ol.2015.3700","article-title":"Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0037","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2015.09.017","article-title":"Improved survival with radiation therapy in stage I-II Primary mediastinal B cell lymphoma: a surveillance, epidemiology, and end results database analysis","volume":"94","author":"Jackson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.clml.2023.08.014_bib0038","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the international extranodal lymphoma study group IELSG-26 study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0039","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0041","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijrobp.2013.05.053","article-title":"Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy","volume":"87","author":"Filippi","year":"2013","journal-title":"J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.clml.2023.08.014_bib0042","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.08.014_bib0043","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hon.2172","article-title":"The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients","volume":"33","author":"Zinzani","year":"2014","journal-title":"Hematol Oncol"},{"issue":"suppl 17","key":"10.1016\/j.clml.2023.08.014_bib0044","article-title":"Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial","volume":"41","author":"Zucca","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.08.014_bib0045","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0046","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ejh.13715","article-title":"End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: prognostic indicator and implications for consolidation radiotherapy","volume":"108","author":"Freitas","year":"2021","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2023.08.014_bib0047","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s00259-017-3758-5","article-title":"Poor predictive value of positive interim FDG-PET\/CT in primary mediastinal large B-cell lymphoma","volume":"44","author":"Lazarovici","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0048","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10428194.2014.910656","article-title":"The utility and limitations of18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review","volume":"56","author":"Cheah","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2023.08.014_bib0049","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-014-2043-y","article-title":"The impact of R-VACOP-B and interim FDG-PET\/CT on outcome in primary mediastinal large B cell lymphoma","volume":"93","author":"Avigdor","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2012","article-title":"Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without rituximab","volume":"31","author":"Papageorgiou","year":"2012","journal-title":"Hematol Oncol"},{"issue":"26","key":"10.1016\/j.clml.2023.08.014_bib0051","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0052","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hon.3096","article-title":"Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era","volume":"41","author":"Vassilakopoulos","year":"2022","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.08.014_bib0053","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1038\/bcj.2015.101","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"5","author":"Aoki","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2023.08.014_bib0054","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41409-017-0063-7","article-title":"Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation","volume":"53","author":"Avivi","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2023.08.014_bib0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2023.08.014_bib0056","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.bbmt.2019.07.041","article-title":"Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma","volume":"25","author":"Herrera","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2023.08.014_bib0057","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/0284186X.2022.2130709","article-title":"Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study","volume":"61","author":"Le Calvez","year":"2022","journal-title":"Acta Oncol (Madr)"},{"issue":"26","key":"10.1016\/j.clml.2023.08.014_bib0058","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.014_bib0059","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018893","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"10254","key":"10.1016\/j.clml.2023.08.014_bib0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet North Am Ed"},{"issue":"14","key":"10.1016\/j.clml.2023.08.014_bib0061","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.08.014_bib0062","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.clml.2023.08.014_bib0063","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.08.014_bib0064","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2021-148082","article-title":"Final analysis of keynote-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL)","volume":"138","author":"Zinzani","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2023.08.014_bib0065","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.08.014_bib0066","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.clml.2023.08.014_bib0067","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.08.014_bib0068","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11864-021-00925-1","article-title":"Bispecific antibodies for non-hodgkin lymphoma treatment","volume":"23","author":"Bock","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.08.014_bib0069","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2023.08.014_bib0070","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.08.014_bib0071","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1186\/s12885-019-6303-z","article-title":"Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma","volume":"19:","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.clml.2023.08.014_bib0072","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/diagnostics12071575","article-title":"Cell-free DNA for genomic analysis in primary mediastinal large B-cell lymphoma","volume":"12","author":"Rivas-Delgado","year":"2022","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.clml.2023.08.014_bib0073","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10428194.2021.2010060","article-title":"Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study","volume":"63","author":"Camus","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.08.014_bib0074","first-page":"4018","article-title":"Determinants of circulating tumor DNA levels across lymphoma histologic subtypes","volume":"130","author":"Schroers-Martin","year":"2017","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2023.08.014_bib0075","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:49Z","timestamp":1761871429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2152265023002744"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in the Management of Primary Mediastinal B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}